Dr. Gold is a national leader in the pursuit of critical questions regarding the epidemiology and pathobiology of acid-related diseases in children, in particular, gastroesophageal reflux disease (GERD) and other esophageal disease (i.e. Eosinophilic Esophagitis, EoE). He has been a key organizer and participant in all of the national and trans-Atlantic, clinical practice guidelines for treatment of pediatric H. pylori infection. In addition, 2005, he established the Aerodigestive Center of Children's Healthcare of Atlanta, and has been the Director of Quality for this multidisciplinary center that now follows almost 300 fragile, medically-complex children with Aerodigestive disease. He is the co-Director of GI Care for Kids site for the Improve Care Now Quality Improvement Collaborative which follows almost 1,100 children with IBD, and, is co-investigator on multiple national pediatric inflammatory bowel disease consortia as well as the evaluation of dietary approaches (i.e. specific carbohydrate diet; SCD) in the management of pediatric IBD. He was a member of the FDA panel establishing GRAS status for Lactobacillus and Bifidobacterium probiotics, and he has been actively involved in characterizing the gut microflora and its relationship to diet and the development and management of IBD, as well as GI allergy and eosinophilic esophagitis, EoE. Dr. Gold has diligently served the North American Society for Pediatric Gastroenterology Hepatology and Nutrition (NASPGHAN) in numerous capacities including being committee chair, being elected to counsel, and most recently, received the honor of being chosen by his peers in Canada, the U.S. and Mexico as the new President-elect of NASPGHAN.
Dr. Gold has published over 155 peer-reviewed manuscripts, over 35 book chapters, is been a sought-after lecturer on upper GI disease in children, as well as, is an international thought leader on pediatric esophageal disease (gastroesophageal reflux disease, GERD; eosinophilic esophagitis, EoE), Helicobacter pylori infection, as well as gut-microbial interactions leading to intestinal inflammation, allergy and immune-mediate disease, including pediatric inflammatory bowel disease (Crohn's and ulcerative colitis).